Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the treatment of choice for the
prevention of atherothrombotic events in patients with acute coronary syndromes and for …

This is one of a series of statements discussing the use of GI endoscopy in common clinical
situations. The Standards of Practice Committee of the American Society for Gastrointestinal …

Objectives: This study sought to compare the action of prasugrel and ticagrelor in ST-
segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous …

Background—Ticagrelor and prasugrel provide stronger platelet inhibition compared with
clopidogrel. Direct pharmacodynamic comparison between them has not yet been reported …

Context Variants in the CYP2C19 gene influence the pharmacologic and clinical response
to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. Objective …

Dual antiplatelet therapy—the combination of aspirin and a P2Y 12-receptor inhibitor—is the
cornerstone of treatment of patients with acute coronary syndromes (ACS) and of those …

Objectives: The study aimed to compare the antiplatelet action of ticagrelor with prasugrel in
acute coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) …

Proton pump inhibitors: potential adverse effects : Current Opinion in Gastroenterology Proton
pump inhibitors: potential adverse effects : Current Opinion in Gastroenterology Log in or …

Our knowledge of the mechanisms of platelet-mediated thrombosis has increased
dramatically over the last 40 years. This increased understanding has identified treatment …

Background Our recent drug interaction trial with clopidogrel shows that morphine
decreases the concentrations and pharmacodynamic effects of clopidogrel, which could …